What was Universal Ibogaine Inc’s price range in the past 12 months?
Universal Ibogaine Inc lowest stock price was €0.00 and its highest was €0.01 in the past 12 months.
What is Universal Ibogaine Inc’s market cap?
Universal Ibogaine Inc’s market cap is €871.43K.
When is Universal Ibogaine Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Universal Ibogaine Inc’s earnings last quarter?
Universal Ibogaine Inc released its earnings results on Jun 27, 2025. The company reported €0 earnings per share for the quarter.
Is Universal Ibogaine Inc overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Universal Ibogaine Inc pay dividends?
Universal Ibogaine Inc does not currently pay dividends.
What is Universal Ibogaine Inc’s EPS estimate?
Universal Ibogaine Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Universal Ibogaine Inc have?
Universal Ibogaine Inc has 274,825,740 shares outstanding.
What happened to Universal Ibogaine Inc’s price movement after its last earnings report?
Universal Ibogaine Inc reported an EPS of €0 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Universal Ibogaine Inc?
Currently, no hedge funds are holding shares in DE:JC4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Universal Ibogaine Inc
Universal Ibogaine Inc. is a life sciences enterprise that focuses on creating, obtaining, and managing addiction treatment centers throughout Canada. The company is also actively involved in scheduled clinical trials, researching the efficacy of ibogaine as a treatment for addiction. Its operations are directed from its head office in Calgary, Canada.